Search research articles
Contact Us
Filters
Showing results (431-440 of 481) with videos related to
Page
of 49
Sort By:
Hemasphere
|
April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
Daniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.
Blood Advances
|
May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
Maria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Blood Advances
|
April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
Simone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Hemasphere
|
February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
Hemasphere
|
May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial
Francesca Cordero, Simone Ferrero, Simone Pernice, et al.
Gynecologic Oncology
|
January 24, 2021
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study
Giorgio Bogani, Andrea Papadia, Alessandro Buda, et al.
Leukemia
|
November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Haematologica
|
March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Gynecologic Oncology
|
June 20, 2022
Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer
Giorgio Bogani, Violante Di Donato, Andrea Papadia, et al.
Hemasphere
|
November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)
Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
Page
of 49
Search research articles
Search
Showing results (431-440 of 481) with videos related to
Sort By:
Page
of 49
Hemasphere
|
April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
Daniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.
Blood Advances
|
May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
Maria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Blood Advances
|
April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
Simone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Hemasphere
|
February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
Hemasphere
|
May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial
Francesca Cordero, Simone Ferrero, Simone Pernice, et al.
Gynecologic Oncology
|
January 24, 2021
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study
Giorgio Bogani, Andrea Papadia, Alessandro Buda, et al.
Leukemia
|
November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Haematologica
|
March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Gynecologic Oncology
|
June 20, 2022
Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer
Giorgio Bogani, Violante Di Donato, Andrea Papadia, et al.
Hemasphere
|
November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)
Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
Page
of 49